's Avatar

@abdelhamid012.bsky.social

52 Followers  |  271 Following  |  11 Posts  |  Joined: 10.01.2025  |  1.7978

Latest posts by abdelhamid012.bsky.social on Bluesky

Post image

Ischemia-reperfusion injury (IRI) is an unavoidable consequence of kidney transplantation, can targeting complement activated via the lectin and alternative pathways help reduce IRI and its clinical impact? Read more in this #ASNJASN #Review kidney.pub/JASN0826

29.08.2025 16:00 β€” πŸ‘ 3    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0

CRS related or immune related podocytopathy

28.08.2025 06:35 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image Post image Post image

2025 Concise Clinical Guidance:
An ACC Expert Consensus Statement on Medical Weight Management for Optimization of Cardiovascular Health

by Drs. Gilbert, @drmarthagulati.bsky.social, Gluckman, @mkittlesonmd.bsky.social, Rikhi, Saseen, Tchang

12.08.2025 19:10 β€” πŸ‘ 8    πŸ” 4    πŸ’¬ 0    πŸ“Œ 0
Post image

What are the best practices for treating patients receiving peritoneal dialysis while hospitalized? This #ASNCJASN "Kidney Case Conference: How I Treat" shares clinician perspective on protocol and procedure. kidney.pub/CJASN0783

18.07.2025 13:00 β€” πŸ‘ 5    πŸ” 3    πŸ’¬ 0    πŸ“Œ 0

NO more with ACEi or ARBs

14.07.2025 09:52 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

Effect of losartan on endothelial function in women with history of #preeclampsia

πŸ”— academic.oup.com/ajh/article/... πŸ”“

#OpenAccess #Free

14.07.2025 08:34 β€” πŸ‘ 5    πŸ” 4    πŸ’¬ 1    πŸ“Œ 2
Post image

Join us for this Global Renal Exercise Group (GREX) Webinar about intradialytic exercise on July 17th. Free registration at: us06web.zoom.us/webinar/regi...

26.06.2025 13:53 β€” πŸ‘ 2    πŸ” 2    πŸ’¬ 0    πŸ“Œ 0
Preview
PREVAIL Investigator on Felzartamab’s Potential to Change IgAN Therapy | Docwire News Dr. George Newman of Knoxville Kidney Center discussed the PREVAIL study of felzartamab for IgA nephropathy (IgAN). Dr. Newman is a site PI for the trial.

CHECK OUT our interview with Dr. George Edward Newman, a PI for the #PREVAIL trial of #felzartamab for #IgAN. His Knoxville site recently dosed its first patient. #nephrology #nephsky #iganephropathy www.docwirenews.com/post/prevail...

26.06.2025 16:57 β€” πŸ‘ 1    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0

Good luck

23.06.2025 20:07 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image Post image Post image Post image

Tirzepatide associated with 1ml/min/yr slower decline in eGfR crcys and decreased albuminuria (30% in those with baseline albuminuria, less for those with normoalbuminuria)! #ada2025

20.06.2025 23:20 β€” πŸ‘ 13    πŸ” 4    πŸ’¬ 1    πŸ“Œ 1

Also PPI could have a roll

21.06.2025 14:24 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Preview
American Society of Nephrology | Media Library - <asp:Literal id=

www.asn-online.org/media/podcas...

18.06.2025 20:08 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

Some conclusions from a great talk on monoclonal gammopathies of renal significance from Dr. Nasr at @glomcon.org today:

25.05.2025 16:14 β€” πŸ‘ 8    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0

More on BEDMED:
youtu.be/mqkTYElw0fo?...
With @rickyturgeon.bsky.social Dr. Scott Garrison @hswapnil.medsky.social and Dr. Isla Mackenzie
@markusathome.bsky.social

16.05.2025 06:02 β€” πŸ‘ 6    πŸ” 3    πŸ’¬ 0    πŸ“Œ 0
Video thumbnail

π—œπ—¦π—‘ π—©π—œπ——π—˜π—’ 𝗔𝗕𝗦𝗧π—₯𝗔𝗖𝗧 π—¦π—˜π—₯π—œπ—˜π—¦: The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial. 2025 from @kidneyint.bsky.social www.kidney-internati...

#VideoAbstract by @drsumanbehera.bsky.social

16.05.2025 12:00 β€” πŸ‘ 4    πŸ” 5    πŸ’¬ 0    πŸ“Œ 0
Post image Post image Post image

Complement activation in secondary thrombotic microangiopathies

doi.org/10.1093/ndt/...

πŸ‘‰This review summarizes the current understanding and future directions in the management of secondary TMA, emphasizing the potential of complement inhibition as therapeutic strategy

15.05.2025 19:18 β€” πŸ‘ 4    πŸ” 3    πŸ’¬ 0    πŸ“Œ 1
Figure 1 Kidney biopsy day 7 post-admission. A. Light microscopy: numerous isometric osmotic vacuoles within tubular epithelial cells (H&E X400). B. Light microscopy: lymphoid infiltrate consistent with CLL within renal parenchyma (H&E x200). C. Electron microscopy: prominent vacuolization within tubular epithelial cells (uranyl acetate and lead citrate x 1000). D. Electron microscopy: higher magnification showing membrane bound osmotic vacuoles seen separate from mitochondria (uranyl acetate and lead citrate x 6000).

Figure 1 Kidney biopsy day 7 post-admission. A. Light microscopy: numerous isometric osmotic vacuoles within tubular epithelial cells (H&E X400). B. Light microscopy: lymphoid infiltrate consistent with CLL within renal parenchyma (H&E x200). C. Electron microscopy: prominent vacuolization within tubular epithelial cells (uranyl acetate and lead citrate x 1000). D. Electron microscopy: higher magnification showing membrane bound osmotic vacuoles seen separate from mitochondria (uranyl acetate and lead citrate x 6000).

Figure 2 Serum creatinine trend to day 15 of hospital admission. Fenofibrate 145mg administered from day 2 to 6, olanzapine 10mg daily from day 1 and gliclazide 60mg twice daily from day 3. Intravenous fluid therapy continued to day 12. Kidney biopsy performed on day 7 (green arrow).

Figure 2 Serum creatinine trend to day 15 of hospital admission. Fenofibrate 145mg administered from day 2 to 6, olanzapine 10mg daily from day 1 and gliclazide 60mg twice daily from day 3. Intravenous fluid therapy continued to day 12. Kidney biopsy performed on day 7 (green arrow).

Interesting case report in @ajkd.bsky.social

Osmotic nephropathy from fenofibrate (or its excipient?)

www.ajkd.org/article/S027...

#NephSky

If true, add to contrast, dextran/starch, mannitol, flozins (pubmed.ncbi.nlm.nih.gov/32387022/)

12.05.2025 22:26 β€” πŸ‘ 17    πŸ” 7    πŸ’¬ 1    πŸ“Œ 0

Any risk to hypoglycemia

11.05.2025 02:18 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Figure 2:eGFR change from baseline over time following dapagliflozin initiation in patients with CKD without type 2 diabetes in the USA in the years 2021–23 (post-approval). *Initiation of dapagliflozin 10 mg.

Figure 2:eGFR change from baseline over time following dapagliflozin initiation in patients with CKD without type 2 diabetes in the USA in the years 2021–23 (post-approval). *Initiation of dapagliflozin 10 mg.

Dapagliflozin in non-diabetic CKD with low/high ACR - OPTIMISE CKD observational design

Pretty flat GFR slopes?

academic.oup.com/ckj/article/... on @ckj-era.bsky.social

#NephSky #OpenAccess

10.05.2025 21:17 β€” πŸ‘ 12    πŸ” 4    πŸ’¬ 2    πŸ“Œ 0
Post image Post image Post image Post image

Lupus nephritis and during pregnancy treatments

13.01.2025 15:22 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

⬇️C3/C4 in kidney dz not a coincidence, it’s about injury to the endothelium:
1. SLE III-IV: subendothelial IC (sEnIC), endocapillary prolif (EnCP)
2. IRGN (bact): EnCP, +/- sEnIC
3. MPGN (viral, idiop): EnCP, sEnIC
4. TMA: compl-endothel injury
5. Atheroemboli: chol cryst-endothel injury
#Nephsky

12.01.2025 01:59 β€” πŸ‘ 16    πŸ” 7    πŸ’¬ 1    πŸ“Œ 0
Post image Post image Post image

www.acpjournals.org/doi/10.7326/...

11.01.2025 09:36 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image Post image

Guidelines should protect patients from non expert But experts should protect patients from guidelines

11.01.2025 08:18 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

Is it applicable for adults ?!!!

11.01.2025 03:27 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Preview
KDIGO GEMs: Glomerular Diseases Join me at #kdigogdgems - A virtual event covering ANCA vasculitis, complement-mediated kidney disease, IgA nephropathy and lupus nephritis

www.gems-gd.org

10.01.2025 18:43 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

@abdelhamid012 is following 19 prominent accounts